A Study of Capmatinib in Lung Cancer Patients

Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!

a study on Lung Cancer Non-Small Cell Lung Cancer

Summary

Eligibility
for people ages 18-90 (full criteria)
Location
at Sacramento, California and other locations
Dates
study started
completion

Description

Summary

This study was planned to determine if neoadjuvant capmatinib could improve the major pathological response (MPR) in patients with Stage IB-IIIA, N2 and selected IIIB (T3N2 or T4N2) lung cancers with Mesenchymal Epithelial Transition (MET) exon 14 mutations and/or high MET amplification beyond those achieved with surgery, chemotherapy, and radiation. Treatment was to be continued with capmatinib in the adjuvant setting to evaluate the potential clinical benefit of extended therapy.

The purpose of this study is to determine if neoadjuvant capmatinib can improve outcomes in participants with stages I-IIIA non-small cell lung cancer with MET exon 14 mutations and/or high MET amplification beyond those achieved with surgery, chemotherapy, and radiation.

Official Title

Phase II Trial of Neoadjuvant and Adjuvant Capmatinib in Participants With Stages IB-IIIA, N2 and Selected IIIB (T3N2 or T4N2) NSCLC With MET Exon 14 Skipping Mutation or High MET Amplification (Geometry-N)

Details

This was a Phase II, two cohort, two stage study of capmatinib given for 8 weeks (2 cycles) prior to surgical resection, followed by three-year capmatinib treatment in adjuvant setting. Surgery had to be performed up to 2 weeks after the last dose of neoadjuvant study treatment.

There were 2 molecularly defined cohorts enrolled in parallel:

  • Cohort A: MET exon 14 skipping mutations, irrespective of MET GCN or
  • Cohort B: high level MET amplification (MET: GCN ≥ 10 by FISH or FoundationOne CDx NGS using tumor tissue).

Approximately 42 participants were aimed to be enrolled in the study, with 21 participants per cohort. This was planned to obtain 38 evaluable participants, 19 per each cohort. Participants who had both MET exon 14 skipping mutations and high-level MET amplification were planned to be enrolled into Cohort A. An evaluable subject received the neoadjuvant treatment and subsequently underwent surgery, resulting in a pathological response.

The study recruitment was prematurely discontinued due to significant recruitment challenges leading to termination of the study. The challenges included the rarity of the mutation and site initiation delays caused by staff shortages associated with COVID-19. As a result, only 4 subjects were enrolled and treated in Cohort A.

Keywords

Non-small Cell Lung Cancer, Mesenchymal Epithelial Transition (MET), MET exon 14 skipping mutation, High MET amplification, Neoadjuvant, Prior to surgery, Adjuvant, After surgery, INC280, MET inhibition, adult, capmatinib, Non-Small-Cell Lung Carcinoma, MET exon 14 skipping mutations

Eligibility

You can join if…

Open to people ages 18-90

  1. Adult ≥ 18 years of age at the time of informed consent.
  2. Histologically confirmed NSCLC Stage IB-IIIA, N2 and selected IIIB (T3N2 or T4N2) (per AJCC 8th edition), deemed suitable for primary resection by treating surgeon (T4 tumors with mediastinal organ invasion were not eligible for enrollment).
  3. Participant must have MET exon 14 mutation and/or high-level MET amplification (MET: GCN ≥ 10) as determined by a CLIA certified laboratory. High level MET amplification must be identified by FISH in a CLIA certified laboratory or FoundationOne CDx NGS (other NGS-based methods without adjusting for tumor content % cannot be accepted).
  4. Participants must be eligible for surgery and scheduled for surgical resection within approximately 2 weeks after the last dose of neoadjuvant study treatment.
  5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.

You CAN'T join if...

  1. Participants with unresectable or metastatic disease. All participants should have brain imaging (either MRI brain or CT brain with contrast) prior to enrollment to exclude brain metastasis.
  2. Presence or history of a malignant disease that has been diagnosed and/or required therapy within the past 3 years. Exceptions to this exclusion include the following: completely resected basal cell and squamous cell skin cancers, and completely resected carcinoma in situ of any type.
  3. Prior treatment with any MET inhibitor or HGF-targeting therapy.
  4. Participants with other known oncogenic driver alterations.
  5. Prior systemic anti-cancer therapy (chemotherapy, immunotherapy, biologic therapy, vaccine) or investigational agents for NSCLC.
  6. Participants with known hypersensitivity to capmatinib and any of the excipients of capmatinib (crospovidone, mannitol, microcrystalline cellulose, povidone, sodium lauryl sulfate, magnesium stearate, colloidal silicon dioxide, and various coating premixes).

Other protocol-defined inclusion/exclusion criteria may apply at the end

Locations

  • University of California Davis Cancer Center .
    Sacramento California 95817 United States
  • University of California Davis Cancer Center
    Sacramento California 95817 United States

Details

Status
accepting new patients
Start Date
Completion Date
Sponsor
Novartis Pharmaceuticals
ID
NCT04926831
Phase
Phase 2 research study
Study Type
Interventional
Participants
About 4 people participating
Last Updated
Contact us about this trial